drugset / Trial / NCT00568321

RN624 For Pain Of Post-Herpetic Neuralgia

NCT00568321

Phase 2 Completed 99 enrolled Pfizer
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will test the efficacy and safety of two doses levels of RN624 versus placebo for the relief of pain caused by post-herpetic neuralgia (PHN).

Timeline

Start
2007-12-19
Primary completion
2008-12-20
Completion
2009-01-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tanezumab Monoclonal antibody 50 ug/kg
Comparator Tanezumab Monoclonal antibody 200 ug/kg